Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Adult
Aged
Aged, 80 and over
Animals
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
BNT162 Vaccine
/ administration & dosage
COVID-19
/ immunology
Chlorocebus aethiops
Female
Humans
Immunoassay
/ methods
Immunoglobulin A
/ blood
Immunoglobulin G
/ blood
Immunoglobulin Isotypes
/ blood
Immunoglobulin M
/ blood
Male
Middle Aged
SARS-CoV-2
/ genetics
Spike Glycoprotein, Coronavirus
/ immunology
Vaccination
/ methods
Vero Cells
COVID-19
SARS-CoV-2
bead
coronavirus
fluorescence
multiplex immunoassay
neutralization assay
serological assay
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
10
2021
accepted:
30
11
2021
entrez:
3
1
2022
pubmed:
4
1
2022
medline:
20
1
2022
Statut:
epublish
Résumé
To compare SARS-CoV-2 antigen-specific antibody production and plasma neutralizing capacity against B.1 wild-type-like strain, and Gamma/P.1 and Delta/B.1.617.2 variants-of-concern, in subjects with different Covid-19 disease and vaccination histories. Adult subjects were: 1) Unvaccinated/hospitalized for Covid-19; 2) Covid-19-recovered followed by one BNT162b2 vaccine dose; and 3) Covid-19-naïve/2-dose BNT162b2 vaccinated. Multiplex Luminex Maximum anti-RBD IgG levels were similar in Covid These findings support SARS-CoV-2 mRNA vaccine usefulness regardless of Covid-19 history, and confirm remarkable protection provided by a single vaccine dose in people who have recovered from Covid-19.
Identifiants
pubmed: 34975897
doi: 10.3389/fimmu.2021.793191
pmc: PMC8718396
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin A
0
Immunoglobulin G
0
Immunoglobulin Isotypes
0
Immunoglobulin M
0
Spike Glycoprotein, Coronavirus
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
793191Informations de copyright
Copyright © 2021 Tarkowski, de Jager, Schiuma, Covizzi, Lai, Gabrieli, Corbellino, Bergna, Ventura, Galli, Riva and Antinori.
Déclaration de conflit d'intérêts
WD was an employee of Luminex Corporation during the study period. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32398307
N Engl J Med. 2021 Jul 15;385(3):239-250
pubmed: 34043894
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Med. 2021 Mar 12;2(3):313-320.e4
pubmed: 33554155
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Nat Rev Immunol. 2020 Dec;20(12):727-738
pubmed: 33139888
Signal Transduct Target Ther. 2020 Sep 2;5(1):180
pubmed: 32879307
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Clin Microbiol Infect. 2022 Jan;28(1):139.e1-139.e4
pubmed: 34508885
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
Biomed Pharmacother. 2021 Nov;143:112107
pubmed: 34488083
Viral Immunol. 2021 Apr;34(3):201-209
pubmed: 33656935
Sci Rep. 2021 Aug 16;11(1):16543
pubmed: 34400714
Vaccines (Basel). 2021 Dec 31;10(1):
pubmed: 35062724
Lancet. 2021 Mar 20;397(10279):1057-1058
pubmed: 33640038
J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9
pubmed: 33221383
Cell Mol Immunol. 2021 Feb;18(2):318-327
pubmed: 33408342
Nat Med. 2021 Jul;27(7):1178-1186
pubmed: 33953384
J Clin Invest. 2021 Jun 15;131(12):
pubmed: 33939647
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
Clin Exp Immunol. 2019 Mar;195(3):287-301
pubmed: 30570135
Microb Cell Fact. 2021 Apr 22;20(1):88
pubmed: 33888152
J Med Virol. 2020 Sep;92(9):1637-1640
pubmed: 32222993
Vaccine. 2021 Jul 13;39(31):4256-4260
pubmed: 34147292
Nat Med. 2021 Jun;27(6):981-984
pubmed: 33795870
Nat Commun. 2021 Jun 28;12(1):3991
pubmed: 34183681
Autoimmun Rev. 2013 Apr;12(6):661-5
pubmed: 23201924
EBioMedicine. 2021 Jun;68:103401
pubmed: 34051441
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
J Infect Public Health. 2021 Oct;14(10):1461-1465
pubmed: 34454862
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Pathophysiology. 2021 May 17;28(2):212-223
pubmed: 35366258
Int J Infect Dis. 2021 Jul;108:176-178
pubmed: 34022329
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Lancet Microbe. 2021 Sep;2(9):e416-e418
pubmed: 34223399
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279